APO Research
Talk to an analyst

APO RESEARCH · REPORT

DNA & RNA Oligonucleotides

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global DNA & RNA Oligonucleotides Market Outlook and Growth Opportunities 2026

30 December 2025191 pages

Choose your research edition.

Industry ResearchDNA & RNA Oligonucleotides Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal DNA & RNA Oligonucleotides Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal DNA & RNA Oligonucleotides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DNA & RNA Oligonucleotides Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal DNA & RNA Oligonucleotides Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global DNA & RNA Oligonucleotides market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for DNA & RNA Oligonucleotides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DNA & RNA Oligonucleotides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DNA & RNA Oligonucleotides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the DNA & RNA Oligonucleotides market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the DNA & RNA Oligonucleotides market include Berry Genomics, BGI, Brooks Life Sciences, Dna Link, Eurofins Scientific, Genotypic Technology, Illumina, LabCorp and Macrogen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global DNA & RNA Oligonucleotides market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DNA & RNA Oligonucleotides and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DNA & RNA Oligonucleotides revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global DNA & RNA Oligonucleotides market.

DNA & RNA Oligonucleotides Segment by Company

Berry Genomics

BGI

Brooks Life Sciences

Dna Link

Eurofins Scientific

Genotypic Technology

Illumina

LabCorp

Macrogen

Natera

Roche

DNA & RNA Oligonucleotides Segment by Type

DNA Oligonucleotides

RNA Oligonucleotides

DNA & RNA Oligonucleotides Segment by Application

Biopharma Companies

Academic & Research Organizations

Hospitals and Clinics

Others

DNA & RNA Oligonucleotides Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global DNA & RNA Oligonucleotides status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the DNA & RNA Oligonucleotides key companies, revenue, market share, and recent developments.

3. To split the DNA & RNA Oligonucleotides breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions DNA & RNA Oligonucleotides market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DNA & RNA Oligonucleotides significant trends, drivers, influence factors in global and regions.

6. To analyze DNA & RNA Oligonucleotides competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA & RNA Oligonucleotides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DNA & RNA Oligonucleotides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA & RNA Oligonucleotides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DNA & RNA Oligonucleotides industry.

Chapter 3: Detailed analysis of DNA & RNA Oligonucleotides company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of DNA & RNA Oligonucleotides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of DNA & RNA Oligonucleotides in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DNA & RNA Oligonucleotides Industry Trends Table 2. DNA & RNA Oligonucleotides Industry Drivers Table 3. DNA & RNA Oligonucleotides Industry Opportunities and Challenges Table 4. DNA & RNA Oligonucleotides Industry Restraints Table 5. Global DNA & RNA Oligonucleotides Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DNA & RNA Oligonucleotides Revenue Share by Company (2021-2026) Table 7. Global DNA & RNA Oligonucleotides Company Ranking, (2024-2026) & (US$ Million) Table 8. Global DNA & RNA Oligonucleotides Key Company Manufacturing Base & Headquarters Table 9. Global DNA & RNA Oligonucleotides Company, Product Type & Application Table 10. Global DNA & RNA Oligonucleotides Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global DNA & RNA Oligonucleotides by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DNA Oligonucleotides Table 15. Significant Companies of RNA Oligonucleotides Table 16. Global DNA & RNA Oligonucleotides Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global DNA & RNA Oligonucleotides Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global DNA & RNA Oligonucleotides Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global DNA & RNA Oligonucleotides Sales Value Share by Type (2021-2026) Table 20. Global DNA & RNA Oligonucleotides Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Biopharma Companies Table 22. Significant Companies of Academic & Research Organizations Table 23. Significant Companies of Hospitals and Clinics Table 24. Significant Companies of Others Table 25. Global DNA & RNA Oligonucleotides Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global DNA & RNA Oligonucleotides Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global DNA & RNA Oligonucleotides Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global DNA & RNA Oligonucleotides Sales Value Share by Application (2021-2026) Table 29. Global DNA & RNA Oligonucleotides Sales Value Share by Application (2027-2032) Table 30. Global DNA & RNA Oligonucleotides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global DNA & RNA Oligonucleotides Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global DNA & RNA Oligonucleotides Sales Value Share by Region (2021-2026) Table 33. Global DNA & RNA Oligonucleotides Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global DNA & RNA Oligonucleotides Sales Value Share by Region (2027-2032) Table 35. Global DNA & RNA Oligonucleotides Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global DNA & RNA Oligonucleotides Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global DNA & RNA Oligonucleotides Sales Value Market Share by Country (2021-2026) Table 38. Global DNA & RNA Oligonucleotides Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global DNA & RNA Oligonucleotides Sales Value Market Share by Country (2027-2032) Table 40. Berry Genomics Company Information Table 41. Berry Genomics Business Overview Table 42. Berry Genomics DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Berry Genomics DNA & RNA Oligonucleotides Product Portfolio Table 44. Berry Genomics Recent Development Table 45. BGI Company Information Table 46. BGI Business Overview Table 47. BGI DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. BGI DNA & RNA Oligonucleotides Product Portfolio Table 49. BGI Recent Development Table 50. Brooks Life Sciences Company Information Table 51. Brooks Life Sciences Business Overview Table 52. Brooks Life Sciences DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Brooks Life Sciences DNA & RNA Oligonucleotides Product Portfolio Table 54. Brooks Life Sciences Recent Development Table 55. Dna Link Company Information Table 56. Dna Link Business Overview Table 57. Dna Link DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Dna Link DNA & RNA Oligonucleotides Product Portfolio Table 59. Dna Link Recent Development Table 60. Eurofins Scientific Company Information Table 61. Eurofins Scientific Business Overview Table 62. Eurofins Scientific DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Eurofins Scientific DNA & RNA Oligonucleotides Product Portfolio Table 64. Eurofins Scientific Recent Development Table 65. Genotypic Technology Company Information Table 66. Genotypic Technology Business Overview Table 67. Genotypic Technology DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Genotypic Technology DNA & RNA Oligonucleotides Product Portfolio Table 69. Genotypic Technology Recent Development Table 70. Illumina Company Information Table 71. Illumina Business Overview Table 72. Illumina DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Illumina DNA & RNA Oligonucleotides Product Portfolio Table 74. Illumina Recent Development Table 75. LabCorp Company Information Table 76. LabCorp Business Overview Table 77. LabCorp DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. LabCorp DNA & RNA Oligonucleotides Product Portfolio Table 79. LabCorp Recent Development Table 80. Macrogen Company Information Table 81. Macrogen Business Overview Table 82. Macrogen DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Macrogen DNA & RNA Oligonucleotides Product Portfolio Table 84. Macrogen Recent Development Table 85. Natera Company Information Table 86. Natera Business Overview Table 87. Natera DNA & RNA Oligonucleotides Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Natera DNA & RNA Oligonucleotides Product Portfolio Table 89. Natera Recent Development Table 90. Roche Company Information Table 91. Roche Business Overview Table 92. Roche DNA & RNA Oligonucleotides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Roche DNA & RNA Oligonucleotides Product Portfolio Table 94. Roche Recent Development Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. DNA & RNA Oligonucleotides Product Image Figure 2. Global DNA & RNA Oligonucleotides Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DNA & RNA Oligonucleotides Market Size (2021-2032) & (US$ Million) Figure 4. Global DNA & RNA Oligonucleotides Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DNA Oligonucleotides Image Figure 8. RNA Oligonucleotides Image Figure 9. Global DNA & RNA Oligonucleotides Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global DNA & RNA Oligonucleotides Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global DNA & RNA Oligonucleotides Sales Value Share by Type (2021-2032) Figure 12. Biopharma Companies Image Figure 13. Academic & Research Organizations Image Figure 14. Hospitals and Clinics Image Figure 15. Others Image Figure 16. Global DNA & RNA Oligonucleotides Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global DNA & RNA Oligonucleotides Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global DNA & RNA Oligonucleotides Sales Value Share by Application (2021-2032) Figure 19. Global DNA & RNA Oligonucleotides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global DNA & RNA Oligonucleotides Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America DNA & RNA Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 22. North America DNA & RNA Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe DNA & RNA Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 24. Europe DNA & RNA Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific DNA & RNA Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific DNA & RNA Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America DNA & RNA Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 28. South America DNA & RNA Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa DNA & RNA Oligonucleotides Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa DNA & RNA Oligonucleotides Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Oligonucleotides
  • RNA Oligonucleotides
Applications
  • Biopharma Companies
  • Academic & Research Organizations
  • Hospitals and Clinics
  • Others
Companies covered
  • Berry Genomics
  • BGI
  • Brooks Life Sciences
  • Dna Link
  • Eurofins Scientific
  • Genotypic Technology
  • Illumina
  • LabCorp
  • Macrogen
  • Natera
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global DNA & RNA Oligonucleotides Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global DNA & RNA Oligonucleotides Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 DNA & RNA Oligonucleotides Market Dynamics
  1. 2.1 DNA & RNA Oligonucleotides Industry Trends
  2. 2.2 DNA & RNA Oligonucleotides Industry Drivers
  3. 2.3 DNA & RNA Oligonucleotides Industry Opportunities and Challenges
  4. 2.4 DNA & RNA Oligonucleotides Industry Restraints
3 DNA & RNA Oligonucleotides Market by Company
  1. 3.1 Global DNA & RNA Oligonucleotides Company Revenue Ranking in 2025
  2. 3.2 Global DNA & RNA Oligonucleotides Revenue by Company (2021-2026)
  3. 3.3 Global DNA & RNA Oligonucleotides Company Ranking (2024-2026)
  4. 3.4 Global DNA & RNA Oligonucleotides Company Manufacturing Base and Headquarters
  5. 3.5 Global DNA & RNA Oligonucleotides Company Product Type and Application
  6. 3.6 Global DNA & RNA Oligonucleotides Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global DNA & RNA Oligonucleotides Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 DNA & RNA Oligonucleotides Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 DNA & RNA Oligonucleotides Market by Type
  1. 4.1 DNA & RNA Oligonucleotides Type Introduction
  2. 4.1.1 DNA Oligonucleotides
  3. 4.1.2 RNA Oligonucleotides
  4. 4.2 Global DNA & RNA Oligonucleotides Sales Value by Type
  5. 4.2.1 Global DNA & RNA Oligonucleotides Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global DNA & RNA Oligonucleotides Sales Value by Type (2021-2032)
  7. 4.2.3 Global DNA & RNA Oligonucleotides Sales Value Share by Type (2021-2032)
5 DNA & RNA Oligonucleotides Market by Application
  1. 5.1 DNA & RNA Oligonucleotides Application Introduction
  2. 5.1.1 Biopharma Companies
  3. 5.1.2 Academic & Research Organizations
  4. 5.1.3 Hospitals and Clinics
  5. 5.1.4 Others
  6. 5.2 Global DNA & RNA Oligonucleotides Sales Value by Application
  7. 5.2.1 Global DNA & RNA Oligonucleotides Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global DNA & RNA Oligonucleotides Sales Value by Application (2021-2032)
  9. 5.2.3 Global DNA & RNA Oligonucleotides Sales Value Share by Application (2021-2032)
6 DNA & RNA Oligonucleotides Regional Value Analysis
  1. 6.1 Global DNA & RNA Oligonucleotides Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DNA & RNA Oligonucleotides Sales Value by Region (2021-2032)
  3. 6.2.1 Global DNA & RNA Oligonucleotides Sales Value by Region: 2021-2026
  4. 6.2.2 Global DNA & RNA Oligonucleotides Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America DNA & RNA Oligonucleotides Sales Value (2021-2032)
  7. 6.3.2 North America DNA & RNA Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe DNA & RNA Oligonucleotides Sales Value (2021-2032)
  10. 6.4.2 Europe DNA & RNA Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific DNA & RNA Oligonucleotides Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific DNA & RNA Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America DNA & RNA Oligonucleotides Sales Value (2021-2032)
  16. 6.6.2 South America DNA & RNA Oligonucleotides Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa DNA & RNA Oligonucleotides Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa DNA & RNA Oligonucleotides Sales Value Share by Country, 2025 VS 2032
7 DNA & RNA Oligonucleotides Country-level Value Analysis
  1. 7.1 Global DNA & RNA Oligonucleotides Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DNA & RNA Oligonucleotides Sales Value by Country (2021-2032)
  3. 7.2.1 Global DNA & RNA Oligonucleotides Sales Value by Country (2021-2026)
  4. 7.2.2 Global DNA & RNA Oligonucleotides Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt DNA & RNA Oligonucleotides Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt DNA & RNA Oligonucleotides Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt DNA & RNA Oligonucleotides Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Berry Genomics
  2. 8.1.1 Berry Genomics Company Information
  3. 8.1.2 Berry Genomics Business Overview
  4. 8.1.3 Berry Genomics DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Berry Genomics DNA & RNA Oligonucleotides Product Portfolio
  6. 8.1.5 Berry Genomics Recent Developments
  7. 8.2 BGI
  8. 8.2.1 BGI Company Information
  9. 8.2.2 BGI Business Overview
  10. 8.2.3 BGI DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BGI DNA & RNA Oligonucleotides Product Portfolio
  12. 8.2.5 BGI Recent Developments
  13. 8.3 Brooks Life Sciences
  14. 8.3.1 Brooks Life Sciences Company Information
  15. 8.3.2 Brooks Life Sciences Business Overview
  16. 8.3.3 Brooks Life Sciences DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Brooks Life Sciences DNA & RNA Oligonucleotides Product Portfolio
  18. 8.3.5 Brooks Life Sciences Recent Developments
  19. 8.4 Dna Link
  20. 8.4.1 Dna Link Company Information
  21. 8.4.2 Dna Link Business Overview
  22. 8.4.3 Dna Link DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dna Link DNA & RNA Oligonucleotides Product Portfolio
  24. 8.4.5 Dna Link Recent Developments
  25. 8.5 Eurofins Scientific
  26. 8.5.1 Eurofins Scientific Company Information
  27. 8.5.2 Eurofins Scientific Business Overview
  28. 8.5.3 Eurofins Scientific DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eurofins Scientific DNA & RNA Oligonucleotides Product Portfolio
  30. 8.5.5 Eurofins Scientific Recent Developments
  31. 8.6 Genotypic Technology
  32. 8.6.1 Genotypic Technology Company Information
  33. 8.6.2 Genotypic Technology Business Overview
  34. 8.6.3 Genotypic Technology DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genotypic Technology DNA & RNA Oligonucleotides Product Portfolio
  36. 8.6.5 Genotypic Technology Recent Developments
  37. 8.7 Illumina
  38. 8.7.1 Illumina Company Information
  39. 8.7.2 Illumina Business Overview
  40. 8.7.3 Illumina DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Illumina DNA & RNA Oligonucleotides Product Portfolio
  42. 8.7.5 Illumina Recent Developments
  43. 8.8 LabCorp
  44. 8.8.1 LabCorp Company Information
  45. 8.8.2 LabCorp Business Overview
  46. 8.8.3 LabCorp DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  47. 8.8.4 LabCorp DNA & RNA Oligonucleotides Product Portfolio
  48. 8.8.5 LabCorp Recent Developments
  49. 8.9 Macrogen
  50. 8.9.1 Macrogen Company Information
  51. 8.9.2 Macrogen Business Overview
  52. 8.9.3 Macrogen DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Macrogen DNA & RNA Oligonucleotides Product Portfolio
  54. 8.9.5 Macrogen Recent Developments
  55. 8.10 Natera
  56. 8.10.1 Natera Company Information
  57. 8.10.2 Natera Business Overview
  58. 8.10.3 Natera DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Natera DNA & RNA Oligonucleotides Product Portfolio
  60. 8.10.5 Natera Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Roche DNA & RNA Oligonucleotides Product Portfolio
  66. 8.11.5 Roche Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst